Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
ICS-H52Ha | Human | Human ICOS / CD278 (C136S, C137S) Protein, His Tag, active dimer (MALS verified) |
![]() ![]() |
![]() ![]() |
|
ICS-R52H9 | Rat | Rat ICOS / CD278 (C137S, C138S) Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
ICS-M5259 | Mouse | Mouse ICOS / CD278 (C137S, C138S) Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
ICS-M52H8 | Mouse | Mouse ICOS / CD278 (C137S, C138S) Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
ICS-H5258 | Human | Human ICOS / CD278 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
ICS-H82E5 | Human | Biotinylated Human ICOS / CD278 (C136S, C137S) Protein, His,Avitag™ (recommended for biopanning) | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Rat ICOS / CD278 (C137S, C138S), His Tag (Cat. No. ICS-R52H9) at 5 μg/mL (100 μL/well) can bind Mouse B7-H2, Fc Tag (Cat. No. B72-M5258) with a linear range of 2-39 ng/mL (QC tested).
The purity of Human ICOS Protein, His Tag (Cat. No. ICS-H52Ha) is more than 90% and the molecular weight of this protein is around 52-62 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Vopratelimab | JTX-2011 | Phase 2 Clinical | Jounce Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Feladilimab | GSK-609; GSK-3359609 | Phase 2 Clinical | Glaxosmithkline Plc | Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Multiple Myeloma | Details |
Acazicolcept | ALPN-101 | Phase 2 Clinical | Alpine Immune Sciences Inc | Autoimmune Diseases; Graft vs Host Disease; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Inflammation | Details |
MEDI-570 | Phase 1 Clinical | Japan Tobacco (Hong Kong) Ltd | Lymphoma, Follicular; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides | Details | |
Izuralimab | XmAb-23104; XmAb-104 | Phase 1 Clinical | Xencor Inc | Triple Negative Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Nasopharyngeal Carcinoma; Solid tumours; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell | Details |
Anti-ICOS (Bristol Myers Squibb) | BMS-986226 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
This web search service is supported by Google Inc.